GoAI
Get started
Coya Therapeutics, Inc. logo

Coya Therapeutics, Inc.

COYA

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$4.87

+$0.01 · +0.21%

COYA company overview

Historical prices · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

84

Deep Value

Momentum

60

Neutral

Sentiment

59

Mixed

Risk resilience

42

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Arun Swaminathan
Listed since
Dec 29, 2022
Employees
8

Market position

Volume
70.95K
0.38× average
Average volume
184.39K
Average daily volume
Market cap
114.24M USD
Beta
0.6
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
50.21M USD
P/E (TTM)
-4.55×
P/B (TTM)
0×
P/S (TTM)
14.25×
EV / EBITDA
-2.37×
Earnings yield
-21.87%
Free cash flow yield
-11.07%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
99.91%
Operating margin
-282.26%
Net margin
-270.22%
Return on equity
-49.33%
Return on assets
-42.49%
Return on invested capital
-45.98%

Financial health

Debt / equity
0×
Current ratio
8.5×
Altman Z-score
-1.12
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends158%-76%-310%-544%Gross margin, FY2023: 8.34%Gross margin, FY2024: -233.86%Gross margin, FY2025: 99.66%Operating margin, FY2023: -131.67%Operating margin, FY2024: -485.35%Operating margin, FY2025: -255.05%Net margin, FY2023: -133.08%Net margin, FY2024: -418.70%Net margin, FY2025: -267.14%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2023 8.34%. Gross margin FY2024 -233.86%. Gross margin FY2025 99.66%. Operating margin FY2023 -131.67%. Operating margin FY2024 -485.35%. Operating margin FY2025 -255.05%. Net margin FY2023 -133.08%. Net margin FY2024 -418.70%. Net margin FY2025 -267.14%.

Income trends

Revenue

7.95M USD+123.57%

Operating income

−20.27M USD-17.48%

Net income

−21.23M USD-42.64%
Income trends across reported periods10.86M USD−805.81K USD−12.47M USD−24.14M USDRevenue, FY2023: 6M USDRevenue, FY2024: 3.55M USDRevenue, FY2025: 7.95M USDOperating income, FY2021: −4.87M USDOperating income, FY2022: −9.81M USDOperating income, FY2023: −7.9M USDOperating income, FY2024: −17.25M USDOperating income, FY2025: −20.27M USDNet income, FY2021: −4.89M USDNet income, FY2022: −12.24M USDNet income, FY2023: −7.99M USDNet income, FY2024: −14.88M USDNet income, FY2025: −21.23M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2023 6M USD. Revenue FY2024 3.55M USD. Revenue FY2025 7.95M USD. Operating income FY2021 −4.87M USD. Operating income FY2022 −9.81M USD. Operating income FY2023 −7.9M USD. Operating income FY2024 −17.25M USD. Operating income FY2025 −20.27M USD. Net income FY2021 −4.89M USD. Net income FY2022 −12.24M USD. Net income FY2023 −7.99M USD. Net income FY2024 −14.88M USD. Net income FY2025 −21.23M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue7.95M USD3.55M USD6M USD——
Cost of goods sold27.36K USD11.87M USD5.5M USD4.41M USD—
Gross profit7.92M USD−8.31M USD500.68K USD−4.41M USD—
Research and development16.73M USD11.89M USD6.04M USD4.94M USD2.54M USD
Selling, general, and administrative11.45M USD8.89M USD7.83M USD4.85M USD2.31M USD
Operating expenses28.18M USD8.94M USD8.4M USD5.4M USD4.87M USD
Depreciation and amortization27.36K USD27.36K USD27.36K USD27.36K USD16.13K USD
Operating income−20.27M USD−17.25M USD−7.9M USD−9.81M USD−4.87M USD
Net income−21.23M USD−14.88M USD−7.99M USD−12.24M USD−4.89M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 6 misses, 1 met estimate
Average EPS surprise
-61.71%
11 comparable reports
Latest EPS result
-0.28
Estimate -0.35 · Beat by 19.01%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.06-0.12-0.3-0.48Q1 '25BeatQ2 '25MetQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 18, 2025: actual -0.18, estimate -0.26, surprise +30.77%, Beat. Q2 2025, reported May 13, 2025: actual -0.44, estimate -0.44, surprise 0.00%, Met estimate. Q3 2025, reported Aug 12, 2025: actual -0.36, estimate -0.22, surprise -63.64%, Miss. Q4 2025, reported Nov 12, 2025: actual -0.1, estimate 0.02, surprise -600.00%, Miss. Q1 2026, reported Mar 16, 2026: actual -0.34, estimate -0.273, surprise -24.77%, Miss. Q2 2026, reported May 12, 2026: actual -0.32, estimate -0.39, surprise +17.95%, Beat. Q3 2026, reported Aug 11, 2026: actual -0.28, estimate -0.346, surprise +19.01%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.39, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates4.32M2.88M1.44M1.66KQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 18, 2025: actual 1.95K USD, estimate 100K USD, surprise -98.05%, Miss. Q2 2025, reported May 13, 2025: actual 257.88K USD, estimate 2.63M USD, surprise -90.21%, Miss. Q3 2025, reported Aug 12, 2025: actual 163.62K USD, estimate 783.33K USD, surprise -79.11%, Miss. Q4 2025, reported Nov 12, 2025: actual 3.56M USD, estimate 1.93M USD, surprise +85.14%, Beat. Q1 2026, reported Mar 16, 2026: actual 4M USD, estimate 2.25M USD, surprise +78.04%, Beat. Q2 2026, reported May 12, 2026: actual 300K USD, estimate 150K USD, surprise +100.00%, Beat. Q3 2026, reported Aug 11, 2026: actual 221.87K USD, estimate 130K USD, surprise +70.67%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate 110K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$12.00

146.41% upside
Past 12 months12-month forecastHigh $12.00Average $12.00Low $12.00

Rating distribution

5 ratings
Strong buy00%
Buy5100%
Hold00%
Sell00%
Strong sell00%

COYA news

businesswire.com

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with…

Read source
zacks.com

Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?

Here is how Coya Therapeutics, Inc. (COYA) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.

Read source
gurufocus.com

Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting

[url="]Coya Therapeutics, Inc.[/url] (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to

Read source
businesswire.com

Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with…

Read source
gurufocus.com

Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease

[url="]Coya Therapeutics, Inc.[/url] (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to

Read source
businesswire.com

Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with…

Read source

COYA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding COYA

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
2.52M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
965.74K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
367.97K
Weight
0.00%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
324.54K
Weight
0.02%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
183.99K
Weight
0.00%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%
Avantis U.S. Small Cap Equity ETF logoAvantis U.S. Small Cap Equity ETFAVSC
Market value
54.52K
Weight
—
AUM
3.16B USD
Expense ratio
0.25%
Price / 1D
$73.84+0.70%
Dimensional - US Vector Equity ETF logoDimensional - US Vector Equity ETFDXUV
Market value
23.34K
Weight
0.00%
AUM
578.74M USD
Expense ratio
0.28%
Price / 1D
$69.80+0.69%
Dimensional - US Core Equity 1 ETF logoDimensional - US Core Equity 1 ETFDCOR
Market value
13.86K
Weight
0.00%
AUM
3.51B USD
Expense ratio
0.14%
Price / 1D
$84.54+0.42%

Continue in GoAI

Research COYA

research.disclaimer